BRPI0409398A - preventivo e/ou remédio para doenças do nervo retinal - Google Patents
preventivo e/ou remédio para doenças do nervo retinalInfo
- Publication number
- BRPI0409398A BRPI0409398A BRPI0409398-4A BRPI0409398A BRPI0409398A BR PI0409398 A BRPI0409398 A BR PI0409398A BR PI0409398 A BRPI0409398 A BR PI0409398A BR PI0409398 A BRPI0409398 A BR PI0409398A
- Authority
- BR
- Brazil
- Prior art keywords
- remedy
- retinal
- retinal nerve
- preventive
- integer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
"PREVENTIVO E/OU REMéDIO PARA DOENçAS DO NERVO RETINAL". Um derivado do éter alquílico representado pela fórmula geral que se segue, ou o seu sal: em que R¬ 1¬ e R¬ 2¬ representam, cada qual, um substituinte, tal que hidrogênio, halogênio ou alquila; R¬ 3¬ representa alquilamino, amino ou hidroxila; o anel A representa um heterociclo aromático de 5 ou 6 membros ou um anel benzeno; m e n são, cada qual, um inteiro de 1 a 6; e p é um inteiro de 1 a 3; apresenta um efeito de proteção das células do nervo retinal e, portanto, é útil como um preventivo e/ou um remédio para doenças do nervo retinal, tais que glaucoma, retinopatia diabética, obstrução da artéria retinal, obstrução venosa retinal, degeneração macular e retinopatia de prematuridade.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003112539 | 2003-04-17 | ||
PCT/JP2004/005355 WO2004091605A1 (ja) | 2003-04-17 | 2004-04-15 | アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409398A true BRPI0409398A (pt) | 2006-04-18 |
Family
ID=33296058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409398-4A BRPI0409398A (pt) | 2003-04-17 | 2004-04-15 | preventivo e/ou remédio para doenças do nervo retinal |
Country Status (20)
Country | Link |
---|---|
US (3) | US20060205709A1 (pt) |
EP (1) | EP1614419B1 (pt) |
JP (1) | JP4642657B2 (pt) |
KR (1) | KR101096528B1 (pt) |
CN (1) | CN100353942C (pt) |
AU (1) | AU2004229283B2 (pt) |
BR (1) | BRPI0409398A (pt) |
CA (1) | CA2521648C (pt) |
CY (1) | CY1113248T1 (pt) |
DK (1) | DK1614419T3 (pt) |
ES (1) | ES2391273T3 (pt) |
IL (1) | IL171388A (pt) |
MX (1) | MXPA05011125A (pt) |
NO (1) | NO334062B1 (pt) |
NZ (1) | NZ543100A (pt) |
PL (1) | PL1614419T3 (pt) |
PT (1) | PT1614419E (pt) |
SI (1) | SI1614419T1 (pt) |
WO (1) | WO2004091605A1 (pt) |
ZA (1) | ZA200508166B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL215264B1 (pl) * | 2001-10-19 | 2013-11-29 | Toyama Chemical Co Ltd | Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna |
DK2389937T3 (en) | 2002-06-14 | 2018-11-12 | Toyama Chemical Co Ltd | Medical composition to improve brain function |
SI2210884T1 (sl) * | 2005-03-28 | 2012-06-29 | Toyama Chemical Co Ltd | Postopek izdelave 1-(3-(2-(1-benzotiofen-5-il)-etoksi)propionske kisline ali soli le-te |
US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
BRPI0710239A2 (pt) * | 2006-04-26 | 2011-08-09 | Toyama Chemical Co Ltd | indutor de neurogênese, e, agente terapêutico para distúrbio mental. |
ATE491705T1 (de) * | 2006-08-04 | 2011-01-15 | Toyama Chemical Co Ltd | Verstärker der aktivität von proteinkinase c, enthaltend ein alkyletherderivat oder ein salz davon |
CN102099397B (zh) | 2008-07-14 | 2012-12-12 | 拜康有限公司 | 合成低聚物的基本单分散混合物的方法 |
ES2721666T3 (es) | 2012-02-22 | 2019-08-02 | Fujifilm Toyama Chemical Co Ltd | Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo |
PT3100725T (pt) * | 2014-01-31 | 2020-06-17 | Fujifilm Toyama Chemical Co Ltd | Agente de melhoria do efeito de reabilitação após uma lesão de um nervo, compreendendo um derivado de éter de alquilo ou um seu sal |
US10238632B2 (en) | 2015-06-11 | 2019-03-26 | Fujifilm Toyama Chemical Co., Ltd. | Sigma receptor-binding agent |
CN108366989B (zh) | 2015-12-25 | 2020-11-03 | 富士胶片富山化学株式会社 | 含有1-(3-(2-(1-苯并噻吩-5-基-)乙氧基)丙基)氮杂环丁-3-醇或其盐的片剂 |
EP3563843A4 (en) | 2016-12-28 | 2019-12-11 | FUJIFILM Toyama Chemical Co., Ltd. | TOPICAL COMPOSITION |
WO2018221728A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | アルツハイマー型認知症予防または治療剤 |
AU2018276638B2 (en) | 2017-06-02 | 2021-04-08 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating brain atrophy |
NZ759647A (en) | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating spinocerebellar ataxia |
CA3067458C (en) | 2017-06-02 | 2022-11-01 | Fujifilm Toyama Chemical Co., Ltd. | Agent for reducing amount of amyloid .beta. protein |
US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2521136A1 (fr) * | 1982-02-05 | 1983-08-12 | Synthelabo | Derives de piperidine, leur preparation et leur application en therapeutique |
US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
DK74693D0 (da) | 1993-06-23 | 1993-06-23 | Novo Nordisk As | Novel heterocyclic chemistry |
TW281667B (pt) * | 1994-02-03 | 1996-07-21 | Synthelabo | |
AU7001796A (en) | 1995-09-22 | 1997-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
JP4549452B2 (ja) * | 1997-12-12 | 2010-09-22 | 富山化学工業株式会社 | アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤 |
AU9235101A (en) * | 2000-10-10 | 2002-04-22 | Toyama Chemical Co Ltd | Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof |
WO2002100833A1 (fr) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
PL215264B1 (pl) * | 2001-10-19 | 2013-11-29 | Toyama Chemical Co Ltd | Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna |
DK2389937T3 (en) * | 2002-06-14 | 2018-11-12 | Toyama Chemical Co Ltd | Medical composition to improve brain function |
-
2004
- 2004-04-15 CN CNB2004800103801A patent/CN100353942C/zh not_active Expired - Fee Related
- 2004-04-15 CA CA2521648A patent/CA2521648C/en not_active Expired - Fee Related
- 2004-04-15 PT PT04727697T patent/PT1614419E/pt unknown
- 2004-04-15 SI SI200431955T patent/SI1614419T1/sl unknown
- 2004-04-15 US US10/553,120 patent/US20060205709A1/en not_active Abandoned
- 2004-04-15 BR BRPI0409398-4A patent/BRPI0409398A/pt not_active Application Discontinuation
- 2004-04-15 MX MXPA05011125A patent/MXPA05011125A/es unknown
- 2004-04-15 EP EP04727697A patent/EP1614419B1/en not_active Expired - Lifetime
- 2004-04-15 PL PL04727697T patent/PL1614419T3/pl unknown
- 2004-04-15 ZA ZA200508166A patent/ZA200508166B/en unknown
- 2004-04-15 KR KR1020057019794A patent/KR101096528B1/ko not_active IP Right Cessation
- 2004-04-15 NZ NZ543100A patent/NZ543100A/en unknown
- 2004-04-15 ES ES04727697T patent/ES2391273T3/es not_active Expired - Lifetime
- 2004-04-15 WO PCT/JP2004/005355 patent/WO2004091605A1/ja active Application Filing
- 2004-04-15 JP JP2005505437A patent/JP4642657B2/ja not_active Expired - Fee Related
- 2004-04-15 AU AU2004229283A patent/AU2004229283B2/en not_active Ceased
- 2004-04-15 DK DK04727697.7T patent/DK1614419T3/da active
-
2005
- 2005-10-11 IL IL171388A patent/IL171388A/en not_active IP Right Cessation
- 2005-10-20 NO NO20054855A patent/NO334062B1/no not_active IP Right Cessation
-
2009
- 2009-08-17 US US12/542,074 patent/US7897594B2/en not_active Expired - Fee Related
-
2011
- 2011-01-19 US US13/008,982 patent/US8067406B2/en not_active Expired - Fee Related
-
2012
- 2012-10-23 CY CY20121100992T patent/CY1113248T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN100353942C (zh) | 2007-12-12 |
DK1614419T3 (da) | 2012-11-19 |
SI1614419T1 (sl) | 2012-12-31 |
PT1614419E (pt) | 2012-10-22 |
CN1774245A (zh) | 2006-05-17 |
ZA200508166B (en) | 2007-03-28 |
US20100075941A1 (en) | 2010-03-25 |
CY1113248T1 (el) | 2016-04-13 |
NO20054855L (no) | 2006-01-09 |
IL171388A (en) | 2010-12-30 |
US20060205709A1 (en) | 2006-09-14 |
EP1614419A4 (en) | 2010-08-18 |
NZ543100A (en) | 2008-07-31 |
KR101096528B1 (ko) | 2011-12-20 |
WO2004091605A1 (ja) | 2004-10-28 |
CA2521648A1 (en) | 2004-10-28 |
AU2004229283A1 (en) | 2004-10-28 |
JP4642657B2 (ja) | 2011-03-02 |
KR20050123167A (ko) | 2005-12-29 |
MXPA05011125A (es) | 2005-12-14 |
CA2521648C (en) | 2012-07-03 |
NO20054855D0 (no) | 2005-10-20 |
EP1614419A1 (en) | 2006-01-11 |
US20110112066A1 (en) | 2011-05-12 |
US7897594B2 (en) | 2011-03-01 |
AU2004229283B2 (en) | 2009-02-05 |
NO334062B1 (no) | 2013-12-02 |
US8067406B2 (en) | 2011-11-29 |
EP1614419B1 (en) | 2012-08-08 |
ES2391273T3 (es) | 2012-11-23 |
PL1614419T3 (pl) | 2013-01-31 |
JPWO2004091605A1 (ja) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0409398A (pt) | preventivo e/ou remédio para doenças do nervo retinal | |
Maher et al. | Flavonoids protect retinal ganglion cells from oxidative stress–induced death | |
US6774142B2 (en) | Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto | |
BR9812048A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia | |
BR0115999A (pt) | Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto | |
BRPI0408189A (pt) | 8'-piridinil-dihidroespiro-[cicloalquil]-pirimido[1,2-a]p irimidin-6-ona substituìda e derivados de 8'-pirimidinil-dihidroespiro-[cicloalquil]-pirimido[1,2- a]pirimidin-6-ona e seus usos contra doenças neurodegenerativas | |
AR030816A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
BRPI0513824A (pt) | derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes | |
UY27333A1 (es) | Nucleótidos 4` sustituidos | |
ES2164972T3 (es) | Derivado substituido de la carboxanilida y agente de control de enfermedades vegetales, el cual lo contiene como ingrediente activo. | |
NO20052028L (no) | Pyridinderivater som CB2 reseptor modulatorer | |
DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
AR007898A1 (es) | Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
BR0211206A (pt) | Derivados de 8-metóxi-(1,2,4)triazolo(1, 5-a)piridina e seus usos como ligantes do receptor de adenosina | |
BRPI0213393B8 (pt) | derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica | |
BRPI0713132B8 (pt) | compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos | |
AR035651A1 (es) | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
CY1119809T1 (el) | Μυκητοκτονος συνθεση και μεθοδος για την καταπολεμηση φυτικης ασθενειας | |
ES2036562T3 (es) | Un procedimiento para produccion de un derivado de pirrolidinamida. | |
BR0211559A (pt) | Compostos, composições de ligantes tetracìclicos terapeuticamente úteis e seus usos | |
BR0213138A (pt) | Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto | |
AR004214A1 (es) | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas | |
Huvaere et al. | Flavonoid deactivation of excited state flavins: Reaction monitoring by mass spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13, 24 E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |